What Alector, Inc. told the SEC could break it.

The majority of operations, including corporate HQ and R&D labs (~105,000 sq ft), are concentrated in one South San Francisco facility, exposing the company to earthquake, fire and other single-site interruption risk.

“The majority of our operations including our corporate headquarters are located in a facility in South San Francisco, California.”

With a $972.1M accumulated deficit and no product revenue, Alector has pledged a first-priority security interest on substantially all assets under its Loan Agreement and may be unable to arrange additional financing.

“As security for our obligations under the Loan Agreement, we granted the collateral agent a first priority security interest on substantially all of our assets, subject to certain exceptions.”

The Inflation Reduction Act of 2022 lets the federal government negotiate maximum fair prices for high-priced single-source Medicare drugs, imposes inflation rebates and penalties — material implications for Alector's future commercialized products.

“In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs”

Alector has no long-term supply agreements and buys drug product on a purchase-order/development-services basis; interruption in limited or sole-sourced raw materials could halt manufacture of its product candidates.

“Any supply interruption in limited or sole sourced raw materials, including those caused by the effects of worldwide economic conditions including pandemics and other public health outbreaks, geopolitical events, export or import restrictions, or trade tariffs, could materially harm our ability to manufacture our product candidates unti”